Article

Multifocals: Careful pre-op preparation minimises explantation

Careful patient selection and precise biometry will all help minimise the risk of later explantation of multifocal IOLs.

Careful patient selection and precise biometry will all help minimise the risk of later explantation of multifocal IOLs, Dr Risto Uusitalo of the Helsinki Eye Clinic said.

"There is a stacking effect, where a number of small errors stack up into a large error. That is why it is vital to get precise biometry, and select appropriate patients," explained Dr Uusitalo.

Exclusion criteria include astigmatism greater than 1.0 D, pre-existing ocular pathology, such as very dense cataract where you can't see the fundus properly, and previous refractive procedure. Physical data is not enough, assessing the psychological profile is also vital.

"A teacher once told me, if your patient has more than three pens in his pocket, be careful. They are typically physicians, architects, engineers and artists. They are perfectionists, they have unrealistic expectations and they are less likely to be happy with loss in vision quality," Dr Uusitalo said.

Similarly, professions that depend on the quality of vision should be excluded too, for example truck drivers.

Dr Uusitalo concluded that multifocal IOLs pose some risks that cannot be ignored, these can, however, be reduced and, overall, the benefits outweigh the risk, for the right patient.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.